

Please type a sign (+) inside this box

PTO/SB/05 (08-00)

Approved for use through 10/31/2002 OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No <i>PT124P1</i>																
		First Inventor <i>FISCELLA, Michele</i>																
		Title B7-Like Polypeptides and Polynucleotides Encoding the Same																
		Express Mail Label No.																
APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231																
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (in duplicate) (Submit on original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages <u>429</u>] <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Brief Description of the Invention - Brief Description of the Drawings (<i>if filed</i>) - Detailed Description - Claim(s) - Abstract of the Disclosure</p> <p>4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>26</u>] <i>(35 U.S.C. 113)</i></p> <p>5. <input checked="" type="checkbox"/> Unexecuted Declaration [Total Pages <u>2</u>] <i>(for continuation/divisional with Box 17 completed)</i></p> <p>a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i></p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) <i>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</i></p> <p>6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76. (3 pages)</p>																		
ACCOMPANYING APPLICATION PARTS																		
<p>9. <input type="checkbox"/> Assignment Papers (cover sheet and document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney</p> <p>11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p> <p>12. <input type="checkbox"/> Information Disclosure Statement/ Form PTO/SB/08 <input type="checkbox"/> Copies of Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(should be specifically itemized)</i></p> <p>15. <input type="checkbox"/> Certified copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Other: Statement Under 37 C.F.R. § 1.821(f)</p>																		
<p>17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76</p> <p><input checked="" type="checkbox"/> See Application Data Sheet for priority information <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of prior application No:</p> <p><i>Prior application information: Examiner _____ Group/Art Unit: _____</i></p> <p><i>For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure if the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts</i></p>																		
<p>18. CORRESPONDENCE ADDRESS</p> <p><input checked="" type="checkbox"/> Customer Number or Bar Code Label <u>22195</u> <input type="checkbox"/> Correspondence address below</p> <table border="1"> <tr> <td>NAME</td> <td colspan="3"></td> </tr> <tr> <td>ADDRESS</td> <td colspan="3"></td> </tr> <tr> <td>CITY</td> <td>STATE</td> <td colspan="2">ZIP CODE</td> </tr> <tr> <td>COUNTRY</td> <td>TELEPHONE</td> <td colspan="2">FAX</td> </tr> </table> <p>NAME (Print/Type) <u>Kenley K. Hover</u> Registration No. (Attorney/Agent) <u>40,302</u> SIGNATURE <u>Kenley K. Hover</u> Date December 20, 2001</p>			NAME				ADDRESS				CITY	STATE	ZIP CODE		COUNTRY	TELEPHONE	FAX	
NAME																		
ADDRESS																		
CITY	STATE	ZIP CODE																
COUNTRY	TELEPHONE	FAX																

* Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

12/20/01

U.S. Patent and Trademark Office
FEE TRANSMITTAL
for FY 2002

(Substitute form)

Patent fees are subject to annual revision.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/17 (7-00)
GPO:2001-032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Total amount of payment

\$776.00

Complete if Known

Application Number	Not assigned
Filing Date	Concurrently Herewith
First Named Inventor	FISCELLA et al.
Examiner Name	Not assigned
Group Art Unit	Not assigned

Attorney Docket Number

PT124P1

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to.
 Deposit Account Number **08-3425**
 Deposit Account Name **Human Genome Sciences, Inc.**
- Charge Any Additional Fee Required
 Under 37 CFR §§ 1.16 and 1.17
- Applicant claims small entity status.
 See 37 CFR 1.27

FEE CALCULATION (continued)

3. ADDITIONAL FEES		Fee Description	Fee Paid
Large Entity Fee Code (\$)	Small Entity Fee Code (\$)		
105	130	205	65
127	50	227	25
139	130	139	130
142	1,280	242	640
195	300	195	300
179	740	279	370
098	130	098	130
126	180	126	180
123	50	123	50
146	740	246	370
149	740	249	370
145	100	145	100
147	2,520	147	2,520
099	8,800	099	8,800
148	110	248	55
115	110	215	55
116	400	216	200
117	920	217	460
118	1,440	218	720
128	1,960	228	980
119	320	219	160
120	320	220	160
121	280	221	140
122	130	122	130
140	110	240	55
141	1,280	241	640
091	1,280	091	1,280
561	3	561	3
581	40	481	40
Other fee (specify):			
Other fee (specify):			
Other fee (specify):			
* Reduced by Basic Filing Fee Paid		SUBTOTAL (3) \$ 0.00	

* or number previously paid, if greater. For Reissues, see above

SUBTOTAL (2) **\$ 36.00****Submitted By**

Name (Print/Type) Kenley K. Hoover

Complete (if applicable)

Registration No.: 40,302

Telephone | 301-610-5771

Signature:

Date: December 20, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 2 hours to complete. Time will vary depending upon the needs of the individual filer. An estimate of the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: FISCELLA et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: B7-Like Polypeptides, and
Polynucleotides Encoding the Same

Attorney Docket No.: PT124P1

STATEMENT UNDER 37 C.F.R. 1.821(f)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby certify that the hard copy of the sequence listing being filed concurrently herewith and the enclosed computer-readable form of such sequence listing are identical.

Respectfully submitted,

Date: December 20 2001



(Reg. No. 40,302)

Kenley K. Hoover
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5771

KKH/JJS/rmr